Listed by the USPTO as ZARA, JANE J
Tech Center 4100 • Art Units: 1600 1632 1635 1637 1641 1658 1674 4100
This examiner grants 71% of resolved cases
ZARA, JANE J is a USPTO patent examiner assigned to Tech Center 4100 and Art Unit 1600. The record includes 1109 resolved cases, with an allowance rate of 71.1%. That volume supports a substantial review of prosecution outcomes.
The median time to allowance is 1062 days, and the interview lift is 16.1%. The measures support early issue management and selective examiner interviews, especially where claim scope or technical distinctions remain contested.
Top companies include Flagship Pioneering Inc., Board of Regents of the University of Texas System, and Sapreme Technologies B V. The listed firms are WOLF GREENFIELD & SACKS, P.C., Knobbe, Martens, Olson & Bear, LLP, and Lathrop GPM LLP.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18277969 | METHODS AND COMPOSITIONS TO CONFER REGULATION TO GENE THERAPY CARGOES BY HETEROLOGOUS USE OF ALTERNATIVE SPLICING CASSETTES | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18535105 | Treatment Of Prion Diseases | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18015108 | NUTRITIONAL COMPOSITION COMPRISING MIR-3184 | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18061632 | TEMPLATE GUIDE RNA MOLECULES | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS VI, LLC |
| 18283257 | COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS VII, LLC |
| 18292421 | METHODS OF PERIPLASMIC PHAGE-ASSISTED CONTINUOUS EVOLUTION | Non-Final OA | President and Fellows of Harvard College |
| 18691216 | COMPOSITIONS COMPRISING DIPEPTIDES AND TRACE ELEMENTS | Non-Final OA | Evonik Operations GmbH |
| 17773682 | TARGETING NONSENSE-MEDIATED DECAY TO ACTIVATE P53 PATHWAY FOR THE TREATMENT OF CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 18283615 | COMPOSITIONS AND METHODS FOR TARGETED SYSTEMIC DELIVERY TO CELLS | Non-Final OA | The Board of Regents of the University of Texas System |
| 17758480 | COMPOSISTIONS AND METHODS FOR CRISPR ENABLED DNA SYNTHESIS | Non-Final OA | Duke University |
| 18533784 | COMPOSITIONS AND METHODS FOR TREATING RIGHT VENTRICLE DYSFUNCTION | Non-Final OA | The United States Government As Represented By The Department Of Veterans Affairs |
| 18389245 | SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17934799 | HIGH PURITY gRNA SYNTHESIS PROCESS | Non-Final OA | CRISPR Therapeutics AG |
| 18039858 | ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS | Non-Final OA | Scribe Therapeutics Inc. |
| 18488520 | ENZYMES WITH RUVC DOMAINS | Final Rejection | Metagenomi Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy71.1% of resolved applications examined by Jane J Zara were allowed (1,109 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.
This examiner's interview lift is +16.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Jane J Zara took 1,062 days on average from filing to allowance.
Jane J Zara examines applications in Art Unit 1600 in Tech Center 4100.